Otonomy Reports Second Quarter 2022 Financial Results and Provides Corporate Update
25. Juli 2022 16:05 ET
|
Otonomy, Inc.
Top-line results for OTO-313 Phase 2 trial in tinnitus expected in August 2022; patient enrollment completed for clinical safety evaluation of higher and bilateral dosing of OTO-313 with top-line...
Otonomy Reports First Quarter 2022 Financial Results and Provides Corporate Update
09. Mai 2022 16:04 ET
|
Otonomy, Inc.
Positive top-line results announced for OTO-413 Phase 2a in hearing loss; enrollment ongoing for higher dose evaluationOTO-313 Phase 2 trial in tinnitus fully enrolled with top-line results expected...
Otonomy to Report First Quarter 2022 Financial Results and Provide Corporate Update
02. Mai 2022 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, May 02, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will...
Otonomy to Host Virtual Investor R&D Event on March 22, 2022
15. März 2022 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, March 15, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
28. Februar 2022 16:27 ET
|
Otonomy, Inc.
OTO-313 Phase 2 trial in tinnitus fully enrolled ahead of schedule with top-line results expected in mid-2022; initiating safety evaluation of higher and bilateral dosingOTO-413 Phase 2a cohort in...
Otonomy to Participate in Two Upcoming Investor Conferences
28. Februar 2022 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
16. November 2021 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its...
Otonomy Announces Publication Supporting Development of OTO-104 as Protectant Against Cisplatin-Induced Hearing Loss
26. Januar 2016 07:05 ET
|
Otonomy, Inc.
SAN DIEGO, Jan. 26, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
12. Januar 2016 09:27 ET
|
Otonomy, Inc.
SAN DIEGO, Jan. 12, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy to Present at J.P. Morgan Healthcare Conference
08. Januar 2016 07:00 ET
|
Otonomy, Inc.
SAN DIEGO, Jan. 08, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...